Navigation Links
Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening

NOIDA, India, Jan. 21 /PRNewswire/ -- Jubilant Organosys Ltd, headquartered in Noida near New Delhi, announced today that its subsidiary Jubilant Biosys Ltd., based in Bangalore, has developed a next generation screening solution, Legend NGSS(TM), that will further enable the process of high throughput screening, accelerating global drug discovery. The software to be launched in the US and Europe initially, allows scientists to capture, store, and analyze Oracle 9i/10g based screening data with greater flexibility, accuracy and speed.

Legend NGSS(TM) allows users to create rich visualization and interactive analysis reports, including dose-response curves and scatter plot heat maps. The novel tool allows flexible and interactive mother to daughter plate mapping from any plate reader. This generates best-fit kinetic and time course assays, without internal IT intervention, complete management of compound and targeted libraries, and optimized on-the fly curve-fitting techniques.

"This novel screening tool for scientific, pharmaceutical and biotech communities around the world can enhance the productivity of pharmaceutical and biotech research," said Christoph Pittius, PhD, Vice President, Global Business Development, Jubilant Biosys.

"This innovative product demonstrates Jubilant's strategy to develop and provide enabling technologies to accelerate the process of Drug Discovery and Development," he added further.

Legend NGSS(TM) has been developed in collaboration with a leading global pharmaceutical company. It is available worldwide on a subscription basis, which includes comprehensive software support and training. The product has generated substantial interest and response during prelaunch activities from global pharmaceutical companies involved in drug discovery.

About Jubilant Biosys

Jubilant Biosys Ltd. headquartered in Bangalore (, is a subsidiary of India-based Jubilant Organosys Ltd. It provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has 125,000 sq. ft. state-of-the-art facility in Bangalore, India. The center houses more than 500 scientists specializing in Bioinformatics, in vitro, in vivo biology, HTS, medicinal chemistry, structural biology, pharmacology, molecular modeling, information technology, and other scientific disciplines. The company has expanded relationships with the global pharmaceutical industry across the drug discovery and development value chain.

Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, the largest custom research and manufacturing services (CRAMS) and drug discovery and development services company out of India. The Company's consolidated sales in FY '07-08 stood at over US$ 600 million.

SOURCE Jubilant Biosys
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Jubilant and BioLeap Announce New Partnership in Drug Discovery
2. SemBioSys announces senior management changes
3. Prosolia and Indigo BioSystems Come Together to Create FireFly(TM) Data Conversion Software for Mass Spectrometers
4. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
5. Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research
6. SemBioSys begins phase I/II trial of insulin produced in plant seeds
7. Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS
8. Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
9. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
10. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
11. SemBioSys announces second quarter 2008 financial and operational results
Post Your Comments:
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... The Academy ... Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the ... last few years. Many AMA members have embraced this type of racing and several ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology Fast 500 list ... facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
(Date:10/27/2015)... , October 27, 2015 ... Automated Semantic Gaze Mapping technology (ASGM) automatically maps data ... Eye Tracking Glasses , so that they can ... --> Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ...
(Date:10/23/2015)... , Oct. 23, 2015 Research and Markets ... "Global Voice Recognition Biometrics Market 2015-2019" report ... --> The global voice recognition biometrics market ... --> --> ... been prepared based on an in-depth market analysis with ...
Breaking Biology News(10 mins):